NASDAQ:CLRB - Cellectar Biosciences Stock Price, Forecast & News

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Shares of Cellectar Biosciences reverse split before market open on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

Cellectar Biosciences Inc (NASDAQ:CLRB) posted its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.04. View Cellectar Biosciences' Earnings History.

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Cellectar Biosciences.

3 brokers have issued 12-month target prices for Cellectar Biosciences' shares. Their forecasts range from $3.00 to $11.00. On average, they anticipate Cellectar Biosciences' stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 162.7% from the stock's current price. View Analyst Price Targets for Cellectar Biosciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectar Biosciences.

News headlines about CLRB stock have trended very positive on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cellectar Biosciences earned a daily sentiment score of 3.4 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Cellectar Biosciences.

Cellectar Biosciences saw a decline in short interest in December. As of December 31st, there was short interest totalling 165,100 shares, a decline of 30.4% from the December 15th total of 237,300 shares. Based on an average daily volume of 122,000 shares, the days-to-cover ratio is currently 1.4 days. Approximately 1.8% of the company's stock are sold short. View Cellectar Biosciences' Current Options Chain.

Some companies that are related to Cellectar Biosciences include Cyclerion Therapeutics (CYCN), Oramed Pharmaceuticals (ORMP), ASLAN PHARMACEU/ADR (ASLN), Enlivex Therapeutics (ENLV), Catalyst Biosciences (CBIO), Elite Pharmaceuticals (ELTP), ESSA Pharma (EPIX), Catabasis Pharmaceuticals (CATB), IMMUTEP LTD/S (IMMP), Aclaris Therapeutics (ACRS), Trevena (TRVN), Eyenovia (EYEN), CTI BioPharma (CTIC), Oncolytics Biotech (ONCY) and Trillium Therapeutics (TRIL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Encana (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy (BNP) and Hudbay Minerals (HBM).

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLRB stock can currently be purchased for approximately $2.54.

Cellectar Biosciences has a market capitalization of $23.86 million. The biopharmaceutical company earns $-13,240,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis. Cellectar Biosciences employs 7 workers across the globe.View Additional Information About Cellectar Biosciences.

The official website for Cellectar Biosciences is http://www.cellectar.com/.

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]